Tsujitani S, Watanabe A, Abe Y, Maehara Y, Sugimachi K, Kaibara N
Department of Surgery I, School of Medicine, Tottori University, Yonago, Japan.
Anticancer Res. 1993 Nov-Dec;13(6B):2497-9.
Intraperitoneal chemotherapy has been attempted to treat peritoneal seeding in patients with gastric cancer. In this study, 13 patients with far advanced gastric cancer were given a complex chemotherapy regimen, cisplatin and etoposide, intraperitoneally during surgery. Cisplatin and etoposide was given 100 mg/body (58-90 mg/m2) and 200 mg/body (115-180 mg/m2), respectively, before closing the abdominal wall. There was one operative death who had an unresectable gastric cancer and died due to respiratory insufficiency, probably related to the drugs. There were no critical side effects due to the drugs among patients who underwent gastrectomy. Postoperative complications encountered were 2 cases of leukopenia, 2 of vomiting, 2 of renal impairment and 1 of liver dysfunction. These complications were transient and limited. The median survival duration was 7.0 months in this study. Thus, intraperitoneal cisplatin and etoposide should be examined for clinical use in larger scale trials.
已尝试采用腹腔内化疗来治疗胃癌患者的腹膜种植转移。在本研究中，13例晚期胃癌患者在手术期间接受了顺铂和依托泊苷的联合化疗方案，通过腹腔内给药。在关闭腹壁前，分别给予顺铂100mg/体（58 - 90mg/m²）和依托泊苷200mg/体（115 - 180mg/m²）。有1例手术死亡患者，其患有不可切除的胃癌，死于呼吸功能不全，可能与药物有关。在接受胃切除术的患者中，未出现因药物导致的严重副作用。术后并发症包括2例白细胞减少、2例呕吐、2例肾功能损害和1例肝功能障碍。这些并发症是短暂且有限的。本研究中患者的中位生存时间为7.0个月。因此，应在更大规模的试验中对腹腔内使用顺铂和依托泊苷进行临床研究。
